Sonnet biotherapeutics completes licensing agreement with new life therapeutics

New life therapeutics (nlt) to develop low-dose interleukin 6 for diabetic peripheral neuropathy in asean territories upfront and potential milestone payments totaling up to $21 million with up to 30% royalties on commercial sales nlt to fund phase 1b/2a clinical trial and submit an ind planned for the second half of 2021 princeton, nj / accesswire / may 3, 2021 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it has executed a definitive agreement with new life therapeutics pte. ltd. (nlt ) of singapore for the license of low-dose interleukin 6, or il-6, for the treatment of diabetic peripheral neuropathy (dpn).
SONN Ratings Summary
SONN Quant Ranking